RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems. As of March 8, 2021, it owned and/or operated 331 centers in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1985 and is headquartered in Los Angeles, California.
IPO Year:
Exchange: NASDAQ
Website: radnet.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/6/2024 | $57.00 → $79.00 | Equal Weight → Overweight | Barclays |
| 3/6/2024 | $48.00 | Equal Weight | Barclays |
| 8/31/2023 | $40.00 | Buy | Truist |
| 3/31/2023 | $30.00 | Market Outperform | CJS Securities |
| 3/3/2023 | $30.00 | Mkt Perform → Outperform | Raymond James |
| 8/12/2021 | Outperform → Market Perform | Raymond James | |
| 8/12/2021 | $39.00 | Overweight | Barclays |
Former Chief Business Leader of Philips' multi-billion-dollar Precision Diagnosis division and member of Philips' Executive CommitteeEnd-to-end responsibility for Philip's CT, MR, dXR, Ultrasound and Diagnostic Informatics (radiology software) businessesProven track record of building and managing radiology software solutions, including significant experience with AI development and commercialization LOS ANGELES, Sept. 12, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers and digital health solutions, announced today the appo
4 - RadNet, Inc. (0000790526) (Issuer)
4 - RadNet, Inc. (0000790526) (Issuer)
4 - RadNet, Inc. (0000790526) (Issuer)
4 - RadNet, Inc. (0000790526) (Issuer)
4 - RadNet, Inc. (0000790526) (Issuer)
4 - RadNet, Inc. (0000790526) (Issuer)
4 - RadNet, Inc. (0000790526) (Issuer)
4 - RadNet, Inc. (0000790526) (Issuer)
4 - RadNet, Inc. (0000790526) (Issuer)
4 - RadNet, Inc. (0000790526) (Issuer)
SCHEDULE 13G/A - RadNet, Inc. (0000790526) (Subject)
8-K - RadNet, Inc. (0000790526) (Filer)
10-Q - RadNet, Inc. (0000790526) (Filer)
8-K - RadNet, Inc. (0000790526) (Filer)
8-K - RadNet, Inc. (0000790526) (Filer)
8-K - RadNet, Inc. (0000790526) (Filer)
8-K - RadNet, Inc. (0000790526) (Filer)
10-Q - RadNet, Inc. (0000790526) (Filer)
8-K - RadNet, Inc. (0000790526) (Filer)
8-K - RadNet, Inc. (0000790526) (Filer)
SC 13G/A - RadNet, Inc. (0000790526) (Subject)
SC 13G/A - RadNet, Inc. (0000790526) (Subject)
SC 13G/A - RadNet, Inc. (0000790526) (Subject)
SC 13G/A - RadNet, Inc. (0000790526) (Subject)
SC 13G - RadNet, Inc. (0000790526) (Subject)
SC 13G/A - RadNet, Inc. (0000790526) (Subject)
SC 13G/A - RadNet, Inc. (0000790526) (Subject)
Total Company Revenue increased 14.7% to $461.1 million in the third quarter of 2024 from $402.0 million in the third quarter of 2023; Revenue from the Digital Health reportable segment (inclusive of intersegment revenue) increased 34.3% to $16.4 million in the third quarter of 2024 from $12.2 million in the third quarter of 2023Digital Health Revenue growth resulted in part from a $2.2 million (or 75.8%) increase in AI Revenue, which climbed to $5.1 million during the third quarter of 2024 from $2.9 million in the third quarter of 2023Total Company Adjusted EBITDA(1) was $73.7 million in the third quarter of 2024 as compared with $57.9 million in the third quarter of 2023, an increase of 27
LOS ANGELES, Oct. 25, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, announced today that it will host a conference call to discuss its third quarter 2024 financial results on Monday, November 11, 2024 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time). Investors are invited to listen to RadNet's conference call by dialing 844-826-3035. International callers can dial 412-317-5195. There will also be simultaneous and archived webcasts available at https://viavid.webcasts.com/starthere.jsp?ei=1691984&tp_key=8cbf05cc88. An arch
Total Company Revenue increased 13.9% to $459.7 million in the second quarter of 2024 from $403.7 million in the second quarter of 2023; Revenue from the Digital Health reportable segment (inclusive of intersegment revenue) increased 36.4% to $15.8 million in the second quarter of 2024 from $11.6 million in the second quarter of 2023Digital Health Revenue growth resulted in part from a $3.2 million (or 136.6%) increase in AI Revenue, which climbed to $5.6 million during the second quarter of 2024 from $2.4 million in the second quarter of 2023Total Company Adjusted EBITDA(1) was $72.3 million in the second quarter of 2024 as compared with $60.4 million in the second quarter of 2023, an incre
LOS ANGELES, July 16, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, announced today that it will host a conference call to discuss its second quarter 2024 financial results on Thursday, August 8, 2024 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time). Investors are invited to listen to RadNet's conference call by dialing 844-826-3035. International callers can dial 412-317-5195. There will also be simultaneous and archived webcasts available at https://viavid.webcasts.com/starthere.jsp?ei=1680804&tp_key=197206db18. An arch
Total Company Revenue increased 10.5% to $431.7 million in the first quarter of 2024 from $390.6 million in the first quarter of 2023; Revenue from the Digital Health reportable segment increased 32.3% to $14.7 million in the first quarter of 2024 from $11.1 million in the first quarter of 2023Digital Health Revenue growth resulted in part from a $2.5 million (or 118.8%) increase in AI Revenue, which climbed to $4.7 million during the first quarter of 2024 from $2.1 million in the first quarter of 2023Total Company Adjusted EBITDA(1) was $58.5 million in the first quarter of 2024 as compared with $48.2 million in the first quarter of 2023, an increase of 21.4%; Digital Health reportable segm
LOS ANGELES, April 22, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, announced today that it will host a conference call to discuss its first quarter 2024 financial results on Thursday, May 9, 2024 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time). Investors are invited to listen to RadNet's conference call by dialing 844-826-3035. International callers can dial 412-317-5195. There will also be simultaneous and archived webcasts available at https://viavid.webcasts.com/starthere.jsp?ei=1667758&tp_key=222b4e91a8. An archived re
Revenue increased 9.5% to a record $420.4 million in the fourth quarter of 2023 from $383.9 million in the fourth quarter of 2022; Excluding Revenue from the Artificial Intelligence ("AI") reporting segment, Revenue from the Imaging Center reporting segment in the fourth quarter of 2023 was $415.3 million, an increase of 8.6% from last year's fourth quarterExcluding losses from the AI reporting segment, Adjusted EBITDA(1) from the Imaging Center reporting segment was a record $68.3 million as compared with $61.6 million in the fourth quarter of 2022, an increase of 11.0%Adjusting for unusual or one-time items impacting Net Income in the quarter, Adjusted Earnings Per Share(3) was $0.20 for t
LOS ANGELES, Feb. 13, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, announced today that it will host a conference call to discuss its fourth quarter 2023 financial results on Friday, March 1, 2024 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time). Investors are invited to listen to RadNet's conference call by dialing 844-826-3035. International callers can dial 412-317-5195. There will also be simultaneous and archived webcasts available at https://viavid.webcasts.com/starthere.jsp?ei=1657167&tp_key=5b49295358. An archived re
LOS ANGELES, Jan. 24, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective outpatient diagnostic imaging services, today announces that its joint ventured Arizona Diagnostic Radiology Group, LLC ("Arizona Diagnostic Radiology") has acquired seven outpatient imaging centers in Phoenix Arizona from Evernorth Care Group. The acquisition will expand outpatient imaging services for Evernorth Care Group patients, who will now have access to Arizona Diagnostic Radiology's nine additional imaging centers in the Phoenix market. Additionally, the newly acquired imaging centers will implement RadNet's digital health solutions, including r
Consolidated Revenue increased 14.8% to $402.0 million in the third quarter of 2023 from $350.0 million in the third quarter of 2022; Excluding Revenue from our Artificial Intelligence ("AI") reporting segment, Revenue from the Imaging Centers reporting segment in the third quarter of 2023 was $399.1 million, an increase of 14.3% from last year's third quarter of $349.1 millionExcluding losses from our AI reporting segment, Adjusted EBITDA(1) from the Imaging Centers reporting segment was $60.4 million in the third quarter of 2023 as compared with $50.2 million in the third quarter of 2022, an increase of 20.3%After adjusting for certain unusual or one-time items impacting the quarters and A
Barclays upgraded RadNet from Equal Weight to Overweight and set a new price target of $79.00 from $57.00 previously
Barclays initiated coverage of RadNet with a rating of Equal Weight and set a new price target of $48.00
Truist initiated coverage of RadNet with a rating of Buy and set a new price target of $40.00
CJS Securities initiated coverage of RadNet with a rating of Market Outperform and set a new price target of $30.00
Raymond James upgraded RadNet from Mkt Perform to Outperform and set a new price target of $30.00
Raymond James downgraded RadNet from Outperform to Market Perform
Barclays initiated coverage of RadNet with a rating of Overweight and set a new price target of $39.00
Raymond James reiterated coverage of RadNet with a rating of Outperform and set a new price target of $26.00 from $22.00 previously
Raymond James reiterated coverage of RadNet with a rating of Outperform and set a new price target of $26.00 from $22.00 previously
LOS ANGELES, Jan. 08, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Dr. Howard Berger, President and Chief Executive Officer, Mark Stolper, Executive Vice President and Chief Financial Officer and Dr. Gregory Sorensen, Executive Vice President and Chief Science Officer will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 15, 2025 at 3:00 p.m. PST. A live webcast of RadNet's presentation can be accessed through the following link, https://jpm
CAMBRIDGE, Mass., Dec. 4, 2024 /PRNewswire/ -- Ketryx announced today that DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly-owned subsidiary of RadNet, Inc. (NASDAQ:RDNT), has selected Ketryx to accelerate the delivery of AI-powered health informatics solutions. DeepHealth's solutions leverage a cloud-native operating system to drive operational efficiency, improved clinical confidence, and better care delivery. According to the FDA, radiology leads the way in AI/ML adoption within the SaMD sector, with 79% of newly approved devices in the field using these technologies to enhance diagnostics and patient care.
At RSNA 2024, DeepHealth launches new AI-powered informatics and SmartTechnology™ solutions powered by DeepHealth OS, its pioneering cloud-native operating system. These solutions, deployed on the secure, scalable, and interoperable OS, address clinical and operational challenges across the imaging value chain.DeepHealth's AI-powered informatics portfolio features the newly introduced Diagnostic Suite™ and TechLive™1, integrated workspaces for radiologists and technologists. In addition, portfolio updates in Radiology Information System (RIS) and clinical AI are showcased. DeepHealth introduces SmartTechnology™, an innovative category of solutions that integrate advanced AI and informatics
LOS ANGELES, Dec. 02, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting at the BofA Securities 2024 Leveraged Finance Conference in Boca Raton, FL on Tuesday, December 3, 2024 at 8:10 a.m. Eastern Time (5:10 a.m. Pacific Time). There will be simultaneous and archived webcasts available at https://bofa.veracast.com/webcasts/bofa/levfin2024/idALc0oT.cfmand www.radnet.com under the "About RadNet'' menu section and "News a
Siemens Healthineers and DeepHealth have signed a letter of intent to create AI-powered SmartTechnology™ to improve patient experience and operational efficiency in ultrasound. The collaboration aims to facilitate remote operations, collaboration, and enhanced interpretation capabilities for increased diagnostic accuracy and consistency by combining Siemens Healthineers' Acuson Sequoia with RadNet's DeepHealth SmartSonography™.A live demonstration of the technology will be held Tuesday, December 3, 10:00 AM – 10:30 AM CT at Booth #2529, South Hall, Level 3 at RSNA 2024, Chicago, IL. LOS ANGELES and SOMERVILLE, Mass., Dec. 01, 2024 (GLOBE NEWSWIRE) -- Siemens Healthineers and DeepHealth, I
Successful deployment achieved across all RadNet sites and 10 million medical reports processed to date Maverick Medical AI announced today the completion of a successful deployment of its real-time autonomous AI-powered medical coding solution across all 399 sites of RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective outpatient diagnostic imaging services. RadNet integrated Maverick Medical AI's mCoder solution to automate the medical coding process. Using deep learning and synthetic data generation, mCoder analyzes reports to accurately generate reimbursement codes in real-time. RadNet has successfully processed more than 10 million reports using M
DeepHealth and CARPL.ai have established a strategic collaboration to create a unique Artificial Intelligence (AI) control system for image interpretation to ensure AI scalability, performance monitoring, and safety, with the aim to accelerate the adoption of AI. DeepHealth currently monitors the performance of DeepHealth's SmartMammo™ AI-powered solution for breast cancer detection at RadNet. Through the collaboration, the two companies aim to expand, productize and scale this control system across more applications to other customers.Furthermore, DeepHealth will embed CARPL.ai's cutting-edge AI orchestration capabilities that enable easy selection, implementation, and monitoring of appropr
SmartMammo™'s AI algorithm now FDA cleared with GE HealthCare's Senographe Pristina™, expanding access to enhanced cancer detection. The clearance enables RadNet's DeepHealth and GE HealthCare collaboration to bring together the SmartMammo and Senographe Pristina solutions and transform breast cancer diagnosis. SOMERVILLE, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Friday, November 29th by RadNet, Inc. (NASDAQ:RDNT), please note that in the third sentence of the first paragraph, the year that SmartMammo Dx was first cleared should be 2021, not 2012. The corrected release follows: DeepHealth, Inc., a wholly-owned subsidiary of RadNet, Inc. (NA
SmartMammo™'s AI algorithm now FDA cleared with GE HealthCare's Senographe Pristina™, expanding access to enhanced cancer detection. The clearance enables RadNet's DeepHealth and GE HealthCare collaboration to bring together the SmartMammo and Senographe Pristina solutions and transform breast cancer diagnosis. SOMERVILLE, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a wholly-owned subsidiary of RadNet, Inc. (NASDAQ:RDNT) and a global leader in AI-powered health informatics, has received expanded FDA 510(k) clearance for its innovative mammography software. SmartMammo Dx, the AI algorithm within SmartMammo1, is now FDA-cleared to be compatible with GE HealthCare
LOS ANGELES, Nov. 22, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services, today announced that it has completed pricing and allocations for Amendment No. 1 to Credit and Guaranty Agreement (the "First Amendment") which will reduce the interest rates payable under its Third Amended and Restated First Lien Credit and Guaranty Agreement (the "Credit Agreement"). RadNet has $872,812,500 of outstanding term loans under the Credit Agreement, and is undrawn on its revolving credit facility. With the successful completion of the First Amendment, the interest rate on the term loans wil